

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:**IN THE CLAIMS**

Please amend the claims as follows, without prejudice to refile:

26. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) binds CD40, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, which amount is effective for the treatment ~~or prevention~~ of cancer.

27. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a purified protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, which amount is effective for the treatment ~~or prevention~~ of cancer.

32. (original) The method of any one of claims 26 or 27 further comprising administering CD40 ligand to the subject.

33. (original) The method of any one of claims 26 or 27 in which the subject is a human.

37. (currently amended) A method for the treatment ~~or prevention~~ of cancer or an immune disorder in a subject comprising administering to the subject, in an amount effective for said treatment ~~or prevention~~: (a) ~~a molecule~~ an antibody that immunospecifically binds CD40, which ~~molecule~~ antibody increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%; and (b) CD40 ligand.

38. (original) The method of claim 26, wherein the molecule is conjugated to a chemotherapeutic agent.

39. (original) The method of claim 27, wherein the protein is conjugated to a chemotherapeutic agent.

40. (currently amended) The method of claim 37, wherein the ~~molecule~~ antibody is conjugated to a chemotherapeutic agent.

41. (currently amended) The method of claim 26 ~~or 37~~, wherein the molecule is purified.

42. (original) The method of any one of claims 38-40, where the subject is a human.

43. (original) The method of claim 26, wherein the molecule is purified, further comprising administering CD40 ligand to the subject.

44. (original) The method of claim 26 or 37, wherein the molecule is a protein.

45. (original) The method of claim 44, wherein the protein is an antibody.

46. (original) The method of claim 45, wherein the antibody comprises a human constant region.
47. (original) The method of claim 46, wherein the antibody is a chimeric antibody.
48. (original) The method of claim 46, wherein the antibody is a humanized antibody.
49. (canceled) The method of claim 46, wherein the antibody is a human antibody.
50. (original) The method of claim 45, wherein the antibody is purified.
51. (original) The method of claim 50, further comprising administering CD40 ligand to the subject.
52. (original) The method of claim 27, wherein the protein is an antibody.
53. (original) The method of claim 52, wherein the antibody comprises a human constant region.
54. (original) The method of claim 53, wherein the antibody is a chimeric antibody.
55. (original) The method of claim 53, wherein the antibody is a humanized antibody.
56. (original) The method of claim 53, wherein the antibody is a human antibody.
57. (original) The method of claim 52, further comprising administering CD40 ligand to the subject.

58. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a molecule comprising SEQ ID NO:8, SEQ ID NO 9, and SEQ ID NO:10, which molecule (a) binds CD40, and (b) is a fusion protein comprising the amino acid sequence of a second molecule that is not an antibody, which amount is effective for the treatment ~~or prevention~~ of cancer, wherein the molecule increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

59. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a molecule comprising SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, which molecule (a) binds CD40, and (b) comprises a human immunoglobulin constant domain, which amount is effective for the treatment ~~or prevention~~ of cancer, wherein the molecule increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

60. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a protein comprising an amino acid sequence that has at least 95% identity to SEQ ID NO:7 ~~as determined by use of the BLASTp computer program~~, which protein (a) binds CD40; and (b) comprises a human immunoglobulin constant domain, which amount is effective for the treatment ~~or prevention~~ of cancer, wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

61. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a protein comprising an amino acid sequence that comprises regions having at least 80% identity to SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively, ~~as determined by use of the BLASTp computer program~~, which protein (a) binds CD40; and (b) comprises a human immunoglobulin constant domain, which amount is effective for the treatment ~~or prevention~~ of cancer, wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

62. (previously presented) The method of claim 61, wherein the protein comprises at least 2 CDR sequences selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO 10.

63. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a molecule that (a) binds to CD40; (b) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%; and (c) comprises a human immunoglobulin constant domain, which amount is effective for the treatment ~~or prevention~~ of cancer.

64. (currently amended) A method for the treatment ~~or prevention~~ of cancer in a subject comprising:

administering to the subject an amount of a molecule which (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-1110; (b) comprises at least 2 CDR sequences selected from the group consisting of SEQ ID NO:8, SEQ ID

NO:9 and SEQ ID NO 10; and (c) comprises a human immunoglobulin constant domain, which amount is effective for the treatment ~~or prevention~~ of cancer, wherein the molecule increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

65. (previously presented) The method of claim 64, wherein the molecule comprises SEQ ID NO:8 and SEQ ID NO:10.

66. (previously presented) The method of claim 58 or 59, wherein the molecule comprises an amino acid sequence of bryodin (BD1) fused to SEQ ID NO:7 fused to SEQ ID NO:2.

67. (previously presented) The method of any of claims 58, 59, 60, and ~~63-66~~ 63, 64, 65, or 66, wherein the molecule is purified.

68. (previously presented) The method of claim 61 or 62, wherein the molecule is purified.

69. (currently amended) The method of any of claims 58, 59, 60, and ~~63-66~~ 63, 64, 65, or 66, wherein the molecule is an antibody.

70. (previously presented) The method of claim 69, wherein the antibody is a chimeric antibody.

71. (previously presented) The method of claim 69, wherein the antibody is a humanized antibody.

72. (previously presented) The method of claim 69, wherein the antibody is a human antibody.

73. (currently amended) The method of any of claims 58, 59, 60, and ~~63-66~~ 63, 64, 65, or 66, wherein the molecule is conjugated to a chemotherapeutic agent.

74. (previously presented) The method of claim 69, wherein the antibody is conjugated to a chemotherapeutic agent.

75. (previously presented) The method of claim 61 or 62, wherein the molecule is an antibody.

76. (previously presented) The method of claim 75, wherein the antibody is a chimeric antibody.

77. (previously presented) The method of claim 75, wherein the antibody is a humanized antibody.

78. (canceled) The method of claim 75, wherein the antibody is a human antibody.

79. (previously presented) The method of claim 61 or 62, wherein the molecule is conjugated to a chemotherapeutic agent.

80. (previously presented) The method of claim 75, wherein the antibody is conjugated to a chemotherapeutic agent.

81. (currently amended) The method of any of claims 58, 59, 60, and ~~63-66~~ 63, 64, 65, or 66, further comprising administering CD40 ligand to the subject.

82. (previously presented) The method of claim 61 or 62, further comprising administering CD40 ligand to the subject.

83. (previously presented) The method of claim 58 or 59, wherein the molecule comprises SEQ ID NO:7.

84. (previously presented) The method of claim 58 or 59, wherein the molecule further comprises SEQ ID NO:2.

85. (previously presented) The method of claim 83, wherein the molecule further comprises SEQ ID NO:2.

86. (canceled) The method of claim 60 or 61, wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

87. (previously presented) The method of claim 27, 60 or 61, wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 50%.

88. (previously presented) The method of claim 27, 60 or 61, wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 60%.

89. (previously presented) The method of claim 27, 60 or 61, wherein the protein increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 65%.

90. (canceled) The method of claim 58, 59 or 64, wherein the molecule increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

91. (previously presented) The method of claim 26, 37, 58, 59, 63 or 64, wherein the molecule increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 50%.

92. (previously presented) The method of claim 26, 37, 58, 59, 63 or 64, wherein the molecule increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 60%.

93. (previously presented) The method of claim 26, 37, 58, 59, 63 or 64, wherein the molecule increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 65%.

94. (previously presented) The method of claim 26, 37, 58, 59, 63 or 64, wherein the method is for treatment of cancer, the subject has cancer, and the cancer is a hematologic malignancy.

95. (previously presented) The method of claim 87, wherein the method is for treatment of cancer, the subject has cancer, and the cancer is a hematologic malignancy.

96. (previously presented) The method of claim 91, wherein the method is for treatment of cancer, the subject has cancer, and the cancer is a hematologic malignancy.

97. (previously presented) The method of claim 26, 37, 58, 59, 63 or 64, wherein the method is for treatment of cancer, the subject has cancer, and the cancer is a carcinoma.

98. (previously presented) The method of claim 87, wherein the method is for treatment of cancer, the subject has cancer, and the cancer is a carcinoma.

99. (previously presented) The method of claim 91, wherein the method is for treatment of cancer, the subject has cancer, and the cancer is a carcinoma.

100. (previously presented) The method of claim 94, wherein the hematologic malignancy is chronic leukemia, lymphoma, or multiple myeloma.

101. (previously presented) The method of claim 95, wherein the hematologic malignancy is chronic leukemia, lymphoma, or multiple myeloma.

102. (previously presented) The method of claim 96, wherein the hematologic malignancy is chronic leukemia, lymphoma, or multiple myeloma.

103. (previously presented) The method of claim 100, wherein the chronic leukemia is chronic myelocytic leukemia or chronic lymphocytic leukemia.

104. (previously presented) The method of claim 101, wherein the chronic leukemia is chronic myelocytic leukemia or chronic lymphocytic leukemia.

105. (previously presented) The method of claim 102, wherein the chronic leukemia is chronic myelocytic leukemia or chronic lymphocytic leukemia.

106. (previously presented) The method of claim 100, wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

107. (previously presented) The method of claim 101, wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

108. (previously presented) The method of claim 102, wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

109. (previously presented) The method of claim 97, wherein the carcinoma is ovarian cancer, lung carcinoma or bladder carcinoma.

110. (previously presented) The method of claim 98, wherein the carcinoma is ovarian cancer, lung carcinoma or bladder carcinoma.

111. (previously presented) The method of claim 99, wherein the carcinoma is ovarian cancer, lung carcinoma or bladder carcinoma.

112. (previously presented) The method of claim 109, wherein the lung carcinoma is small cell lung carcinoma or non-small cell lung carcinoma.

113. (previously presented) The method of claim 110, wherein the lung carcinoma is small cell lung carcinoma or non-small cell lung carcinoma.

114. (previously presented) The method of claim 111, wherein the lung carcinoma is small cell lung carcinoma or non-small cell lung carcinoma.